BTN2 Antibody

Structure and Target Specificity

BTN2 antibodies are immunoglobulin molecules with a Y-shaped structure composed of two heavy and two light chains . Their antigen-binding region (Fab) targets BTN2A1 and BTN2A2, transmembrane proteins expressed on immune cells such as γδ T cells, dendritic cells, and macrophages . Key features include:

• Specificity: High affinity for BTN2A1/A2, with cross-reactivity to orthologs in other species .

• Functional Domains:

  • Fab region: Binds BTN2 extracellular domains.

  • Fc region: Determines effector functions (e.g., antibody-dependent cellular cytotoxicity) .

In Vitro and Preclinical Data

• Cancer Models: Anti-BTN2 antibodies synergize with anti-PD-1 therapy, enhancing CD8+ T cell infiltration and reducing myeloid-derived suppressor cells (MDSCs) .

• Autoimmune Disease: BTN2A2-Ig fusion protein suppresses T cell proliferation and Th1/Th17 cytokines in murine collagen-induced arthritis .

Clinical Relevance

• BTN2 overexpression correlates with poor survival in solid cancers .

• Antibody-mediated BTN2 blockade extends survival in metastatic tumor models .

Therapeutic Applications

• Cancer Immunotherapy:

  • Reduces IL-17A-driven immune suppression in the tumor microenvironment .

  • Enhances efficacy of checkpoint inhibitors (e.g., anti-PD-1) .

• Autoimmune Disorders:

  • BTN2A2-Ig fusion protein ameliorates arthritis by dampening T cell activation .

Comparative Analysis of BTN2 Antibodies

Future Directions

• Combination Therapies: Pairing BTN2 antibodies with checkpoint inhibitors or CAR-T cells.

• Humanization: Engineering silent (low ADCC) variants to minimize off-target effects .

• Biomarker Development: Correlating BTN2 expression levels with therapeutic response .